18th Oct 2007 12:21
ABCAM Plc18 October 2007 For immediate release 18 October 2007 ABCAM PLC ("Abcam" or "the Company") Directors' Dealings Cambridge UK, 18 October 2007: Abcam plc announces that, on 17 October 2007, it approved the exercise of a number of share options to certain Directors of the Company: Eddie Powell (Finance Director) - 40,000 options exercised under the Abcam plcUnapproved Option Scheme, at an exercise price of 62.5 pence per share; Jim Warwick (Managing Director) - 32,000 options exercised under the First Abcamplc EMI Option Scheme, at an exercise price of 37.5 pence per share. Eddie Powell subsequently sold 150,000 ordinary shares of 1p each in the Companyat a price of 315 pence per share on 17 October 2007. Following this transaction Eddie Powell's has an interest of 526,240 shares representing approximately 1.51% of the Company's issued share capital. Jim Warwick subsequently sold 32,000 ordinary shares of 1p each in the Company at a price of 315 pence per share on 17 October 2007. Following this transaction Jim Warwick's interest in Abcam is unchanged at 826,200 shares representing approximately 2.37% of the Company's issued share capital. For further information please contact: Abcam + 44 (0) 1223 696000Jonathan Milner, Chief Executive OfficerEddie Powell, Chief Financial Officerwww.abcam.com Numis Securities + 44 (0) 20 7776 1500James Black Buchanan Communications + 44 (0) 20 7466 5000Mark Court / Mary-Jane Johnson Notes for editors: About Abcam plc Abcam is a producer and distributor of research-grade antibodies headquarteredin Cambridge, UK, with a US office located in Cambridge, Massachusetts and aJapanese office in Tokyo. Abcam was admitted to AIM in November 2005 and tradesunder the ticker symbol ABC. The Company produces and distributes its own andthird party produced antibodies to academic and commercial users throughout theworld with product information provided and ordering available through theCompany's website, www.abcam.com. The antibodies are sold under the Abcam brandname. The Company's vision is to build the largest online antibody resource inthe world while also ensuring that the antibodies are of high quality andcommercially viable. Abcam now has an online catalogue of approximately 36,000products, most of which are antibodies, from over 200 suppliers supported byup-to-date and detailed technical data sheets, which are created by the Company.The Company currently employs 140 staff in its three operating companies. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
ABC.L